DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Golvatinib

Generic Name: Golvatinib

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₇F_₂N_₇O_₄

CAS Number: 928037-13-2

Unique Ingredient Identifier: 516Z3YP58E

Overview

Golvatinib has been investigated for the treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck.

Background

Golvatinib has been investigated for the treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers

Phase 1

Completed

Posted: 2015/08/26

Sponsor:Eisai Limited

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Phase 1

Terminated

Posted: 2011/09/14

Sponsor:Eisai Inc.

A Phase I Study of E7050 in Subjects With Solid Tumors

Phase 1

Completed

Posted: 2011/09/02

Sponsor:Eisai Co., Ltd.

E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer

Phase 1

Terminated

Posted: 2011/05/18

Sponsor:Eisai Inc.

E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

Phase 1

Completed

Posted: 2011/04/11

Sponsor:Eisai Inc.

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy